Table 1. Clinical features of patients with CXCR4+ and CXCR4− expression in overall, GCB-DLBCL and ABC-DLBCL.
| DLBCL | GCB-DLBCL | ABC-DLBCL | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variables | CXCR4+ N(%) | CXCR4− N(%) | P | CXCR4+ N(%) | CXCR4− N(%) | P | CXCR4+ N(%) | CXCR4− N(%) | P |
| Age, years | |||||||||
| < 60 | 51(37.8) | 147(44.1) | .21 | 28(53.8) | 93(50.5) | .67 | 23(27.7) | 53(36.3) | .18 |
| ≥ 60 | 84(62.2) | 18655.9% | 24(46.2) | 91(49.5) | 60(72.3) | 93(63.7) | |||
| Gender | |||||||||
| F | 40(29.6) | 148(44.4) | .0031 | 18(34.6) | 78(42.4) | .31 | 22(26.5) | 69(47.3) | .002 |
| M | 95(70.4) | 185(55.6) | 34(65.4) | 106(57.6) | 61(73.5) | 77(52.7) | |||
| Stage | |||||||||
| I - II | 56(42.4) | 155(48.3) | .26 | 23(45.1) | 98(55.7) | .18 | 33(40.7) | 55(39) | .80 |
| III - IV | 76(57.6) | 166(51.7) | 28(54.9) | 78(44.3) | 48(59.3) | 86(61.0) | |||
| B-symptoms | |||||||||
| No | 84(65.6) | 206(64.8) | .87 | 34(70.8) | 123(70.3) | .94 | 50(62.5) | 80(57.6) | .47 |
| Yes | 44(34.4) | 112(35.2) | 14(29.2) | 52(29.7) | 30(37.5) | 59(42.4) | |||
| LDH level | |||||||||
| Normal | 45(36.6) | 122(39.9) | .53 | 19(42.2) | 72(42.6) | .96 | 26(33.3) | 49(36.8) | .61 |
| Elevated | 78(63.4) | 184(60.1) | 26(57.8) | 97(57.4) | 52(66.7) | 84(63.2) | |||
| Number of extranodal sites | |||||||||
| 0 - 1 | 94(73.3) | 251(79.9) | .089 | 35(72.9) | 140(80) | .29 | 59(71.1) | 108(77.7) | .27 |
| ≥ 2 | 37(26.7) | 66(20.1) | 13(27.1) | 35(20) | 24(28.9) | 31(22.3) | |||
| ECOG Performance status | |||||||||
| 0 - 1 | 104(85.2) | 243(82.9) | .56 | 39(90.7) | 134(83.8) | .25 | 65(82.3) | 106(81.5) | .89 |
| ≥ 2 | 18(14.8) | 50(17.1) | 4(9.3) | 26(16.3) | 14(17.7) | 24(18.5) | |||
| Size of largest tumor | |||||||||
| < 5cm | 55(49.1) | 151(62.1) | .02 | 22(75.9) | 82(60.3) | .11 | 33(45.2) | 67(65) | .0088 |
| ≥ 5cm | 57(50.9) | 92(37.9) | 7(24.1) | 54(39.7) | 40(54.8) | 36(35) | |||
| IPI score | |||||||||
| 0 - 2 | 74(57.4) | 208(64.4) | .16 | 31(64.6) | 125(70.6) | .42 | 43(53.1) | 80(56.3) | .64 |
| 3 - 5 | 55(42.6) | 115(35.6) | 17(35.4) | 52(29.4) | 38(46.9) | 62(43.7) | |||
| Therapy response | |||||||||
| CR | 102(75.6) | 261(78.4) | .51 | 35(67.3) | 148(80.4) | .045 | 67(80.7) | 111(76) | .41 |
| PR | 13 | 45 | 5 | 21 | 8 | 24 | |||
| SD | 8 | 11 | 5 | 7 | 3 | 4 | |||
| PD | 12 | 16 | 7 | 8 | 5 | 7 | |||
| COO | |||||||||
| GCB | 52(38.5) | 184(55.8) | .0008 | ||||||
| ABC | 83(61.5) | 146(44.2) | |||||||
Abbreviations: LDH, lactate dehydrogenase; IPI, International Prognostic Index; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; COO, cell-of-origin. For therapy response, we calculated P values as CR vs other responses. Few clinical features of certain cases were not available.